ABSTRACT
Cytochrome c oxidase (COX) deficiency is characterized by a high degree of genetic and phenotypic heterogeneity, partly reflecting the extreme structural complexity, multiple post-translational modification, variable, tissue-specific composition, and the high number of and intricate connections among the assembly factors of this enzyme. In fact, decreased COX specific activity can manifest with different degrees of severity, affect the whole organism or specific tissues, and develop a wide spectrum of disease natural history, including disease onsets ranging from birth to late adulthood. More than 30 genes have been linked to COX deficiency, but the list is still incomplete and in fact constantly updated. We here discuss the current knowledge about COX in health and disease, focusing on genetic aetiology and link to clinical manifestations. In addition, information concerning either fundamental biological features of the enzymes or biochemical signatures of its defects have been provided by experimental in vivo models, including yeast, fly, mouse and fish, which expanded our knowledge on the functional features and the phenotypical consequences of different forms of COX deficiency.
Subject(s)
Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/genetics , Electron Transport Complex IV/genetics , Electron Transport Complex IV/metabolism , Animals , Disease Models, Animal , Humans , MiceABSTRACT
Leigh syndrome French Canadian type (LSFC) is a mitochondrial disease caused by mutations in the leucine-rich pentatricopeptide repeat-containing (LRPPRC) gene leading to a reduction of cytochrome-c oxidase (COX) expression reaching 50% in skin fibroblasts. We have shown that under basal conditions, LSFC and control cells display similar ATP levels. We hypothesized that this occurs through upregulation of mechanistic target of rapamycin (mTOR)-mediated metabolic reprogramming. Our results showed that compared with controls, LSFC cells exhibited an upregulation of the mTOR complex 1 (mTORC1)/p70 ribosomal S6 kinase pathway and higher levels of hypoxia-inducible factor 1α (HIF-1α) and its downstream target pyruvate dehydrogenase kinase 1 (PDHK1), a regulator of mitochondrial pyruvate dehydrogenase 1 (PDH1). Consistent with these signaling alterations, LSFC cells displayed a 40-61% increase in [U-13C6]glucose contribution to pyruvate, lactate, and alanine formation, as well as higher levels of the phosphorylated and inactive form of PDH1-α. Interestingly, inhibition of mTOR with rapamycin did not alter HIF-1α or PDHK1 protein levels in LSFC fibroblasts. However, this treatment increased PDH1-α phosphorylation in control and LSFC cells and reduced ATP levels in control cells. Rapamycin also decreased LRPPRC expression by 41 and 11% in LSFC and control cells, respectively, and selectively reduced COX subunit IV expression in LSFC fibroblasts. Taken together, our data demonstrate the importance of mTORC1, independent of the HIF-1α/PDHK1 axis, in maintaining LRPPRC and COX expression in LSFC cells.
Subject(s)
Cytochrome-c Oxidase Deficiency/enzymology , Electron Transport Complex IV/metabolism , Fibroblasts/enzymology , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Leigh Disease/enzymology , Mechanistic Target of Rapamycin Complex 1/metabolism , Neoplasm Proteins/metabolism , Skin/enzymology , Adenosine Triphosphate/metabolism , Cells, Cultured , Child , Cytochrome-c Oxidase Deficiency/genetics , Cytochrome-c Oxidase Deficiency/pathology , Electron Transport Complex IV/genetics , Energy Metabolism , Female , Fibroblasts/pathology , Gene Expression Regulation, Enzymologic , Glucose/metabolism , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Leigh Disease/genetics , Leigh Disease/pathology , Mechanistic Target of Rapamycin Complex 1/genetics , Mitochondria/enzymology , Mitochondria/pathology , Neoplasm Proteins/genetics , Pyruvate Dehydrogenase Acetyl-Transferring Kinase/genetics , Pyruvate Dehydrogenase Acetyl-Transferring Kinase/metabolism , Pyruvate Dehydrogenase Complex/genetics , Pyruvate Dehydrogenase Complex/metabolism , Quebec , Signal Transduction , Skin/pathologyABSTRACT
Defects in the respiratory chain, interfering with energy production in the cell, are major underlying causes of mitochondrial diseases. In spite of this, the surprising variety of clinical symptoms, disparity between ages of onset, as well as the involvement of mitochondrial impairment in ageing and age-related diseases continue to challenge our understanding of the pathogenic processes. This complexity can be in part attributed to the unique metabolic needs of organs or of various cell types. In this view, it remains essential to investigate mitochondrial dysfunction at the cellular level. For this purpose, we developed a novel enzyme histochemical method that enables precise quantification in fresh-frozen tissues using competing redox reactions which ultimately lead to the reduction of tetrazolium salts and formazan deposition in cytochrome c oxidase-deficient mitochondria. We demonstrate that the loss of oxidative activity is detected at very low levels - this achievement is unequalled by previous techniques and opens up new opportunities for the study of early disease processes or comparative investigations. Moreover, human biopsy samples of mitochondrial disease patients of diverse genotypic origins were used and the successful detection of COX-deficient cells suggests a broad application for this new method. Lastly, the assay can be adapted to a wide range of tissues in the mouse and extends to other animal models, which we show here with the fruit fly, Drosophila melanogaster. Overall, the new assay provides the means to quantify and map, on a cell-by-cell basis, the full extent of COX deficiency in tissues, thereby expending new possibilities for future investigation. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
Subject(s)
Cytochrome-c Oxidase Deficiency/diagnosis , Electron Transport Complex IV/metabolism , Single-Cell Analysis/methods , Staining and Labeling/methods , Animals , Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/genetics , Disease Models, Animal , Drosophila Proteins/metabolism , Drosophila melanogaster , Energy Metabolism , Humans , Membrane Proteins/deficiency , Membrane Proteins/genetics , Methylphenazonium Methosulfate/chemistry , Mice, Inbred C57BL , Mice, Knockout , Mitochondrial Proteins/deficiency , Mitochondrial Proteins/genetics , Mutation , Neoplasm Proteins/deficiency , Neoplasm Proteins/genetics , Nitroblue Tetrazolium/chemistry , Oxidation-Reduction , Predictive Value of Tests , RNA, Transfer, Ala/geneticsABSTRACT
Leigh syndrome (LS) is a rare progressive neurodegenerative disorder occurring in infancy. The most common clinical signs reported in LS are growth retardation, optic atrophy, ataxia, psychomotor retardation, dystonia, hypotonia, seizures and respiratory disorders. The paper reported a manifestation of 3 Tunisian patients presented with LS syndrome. The aim of this study is the MT[HYPHEN]ATP6 and SURF1 gene screening in Tunisian patients affected with classical Leigh syndrome and the computational investigation of the effect of detected mutations on its structure and functions by clinical and bioinformatics analyses. After clinical investigations, three Tunisian patients were tested for mutations in both MT-ATP6 and SURF1 genes by direct sequencing followed by in silico analyses to predict the effects of sequence variation. The result of mutational analysis revealed the absence of mitochondrial mutations in MT-ATP6 gene and the presence of a known homozygous splice site mutation c.516-517delAG in sibling patients added to the presence of a novel double het mutations in LS patient (c.752-18 A > C/c. c.751 + 16G > A). In silico analyses of theses intronic variations showed that it could alters splicing processes as well as SURF1 protein translation. Leigh syndrome (LS) is a rare progressive neurodegenerative disorder occurring in infancy. The most common clinical signs reported in LS are growth retardation, optic atrophy, ataxia, psychomotor retardation, dystonia, hypotonia, seizures and respiratory disorders. The paper reported a manifestation of 3 Tunisian patients presented with LS syndrome. The aim of this study is MT-ATP6 and SURF1 genes screening in Tunisian patients affected with classical Leigh syndrome and the computational investigation of the effect of detected mutations on its structure and functions. After clinical investigations, three Tunisian patients were tested for mutations in both MT-ATP6 and SURF1 genes by direct sequencing followed by in silico analysis to predict the effects of sequence variation. The result of mutational analysis revealed the absence of mitochondrial mutations in MT-ATP6 gene and the presence of a known homozygous splice site mutation c.516-517delAG in sibling patients added to the presence of a novel double het mutations in LS patient (c.752-18 A>C/ c.751+16G>A). In silico analysis of theses intronic vaiations showed that it could alters splicing processes as well as SURF1 protein translation.
Subject(s)
Cytochrome-c Oxidase Deficiency/enzymology , Electron Transport Complex IV/metabolism , Leigh Disease/genetics , Membrane Proteins/genetics , Mitochondrial Proteins/genetics , Mitochondrial Proton-Translocating ATPases/genetics , Brain/diagnostic imaging , Child , Child, Preschool , Computer Simulation , DNA Mutational Analysis , Humans , Magnetic Resonance Imaging , Male , Mutation , RNA Splicing , TunisiaABSTRACT
The relationships between the molecular abnormalities in mitochondrial respiratory chain complexes and their negative contributions to mitochondrial and cellular functions have been proved to be essential for better understandings in mitochondrial medicine. Herein, we established the method to identify disease phenotypic differences among patients with muscle histopathological cytochrome c oxidase (COX) deficiency, as one of the representative clinical features in mitochondrial diseases, by using patients' myoblasts that are derived from biopsied skeletal muscle tissues. We identified two obviously different severities in molecular diagnostic criteria of COX deficiency among patients: structurally stable, but functionally mild/moderate defect and severe functional defect with the disrupted COX holoenzyme structure. COX holoenzyme disorganization actually triggered several mitochondrial dysfunctions, including the decreased ATP level, the increased oxidative stress level, and the damaged membrane potential level, all of which lead to the deteriorated cellular growth, the accelerated cellular senescence, and the induced apoptotic cell death. Our cell-based in vitro diagnostic approaches would be widely applicable to understanding patient-specific pathomechanism in various types of mitochondrial diseases, including other respiratory chain complex deficiencies and other mitochondrial metabolic enzyme deficiencies.
Subject(s)
Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/pathology , Electron Transport Complex IV/metabolism , Mitochondria/metabolism , Cytochrome-c Oxidase Deficiency/diagnosis , Cytochrome-c Oxidase Deficiency/genetics , Holoenzymes/metabolism , Homeostasis , Humans , Models, Biological , Muscle Development , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Mutation/genetics , Phenotype , RNA, Messenger/genetics , RNA, Messenger/metabolismABSTRACT
Mitochondrial Complex IV [cytochrome c oxidase (COX)] deficiency is one of the most common respiratory chain defects in humans. The clinical phenotypes associated with COX deficiency include liver disease, cardiomyopathy and Leigh syndrome, a neurodegenerative disorder characterized by bilateral high signal lesions in the brainstem and basal ganglia. COX deficiency can result from mutations affecting many different mitochondrial proteins. The French-Canadian variant of COX-deficient Leigh syndrome is unique to the Saguenay-Lac-Saint-Jean region of Québec and is caused by a founder mutation in the LRPPRC gene. This encodes the leucine-rich pentatricopeptide repeat domain protein (LRPPRC), which is involved in post-transcriptional regulation of mitochondrial gene expression. Here, we present the clinical and molecular characterization of novel, recessive LRPPRC gene mutations, identified using whole exome and candidate gene sequencing. The 10 patients come from seven unrelated families of UK-Caucasian, UK-Pakistani, UK-Indian, Turkish and Iraqi origin. They resemble the French-Canadian Leigh syndrome patients in having intermittent severe lactic acidosis and early-onset neurodevelopmental problems with episodes of deterioration. In addition, many of our patients have had neonatal cardiomyopathy or congenital malformations, most commonly affecting the heart and the brain. All patients who were tested had isolated COX deficiency in skeletal muscle. Functional characterization of patients' fibroblasts and skeletal muscle homogenates showed decreased levels of mutant LRPPRC protein and impaired Complex IV enzyme activity, associated with abnormal COX assembly and reduced steady-state levels of numerous oxidative phosphorylation subunits. We also identified a Complex I assembly defect in skeletal muscle, indicating different roles for LRPPRC in post-transcriptional regulation of mitochondrial mRNAs between tissues. Patient fibroblasts showed decreased steady-state levels of mitochondrial mRNAs, although the length of poly(A) tails of mitochondrial transcripts were unaffected. Our study identifies LRPPRC as an important disease-causing gene in an early-onset, multisystem and neurological mitochondrial disease, which should be considered as a cause of COX deficiency even in patients originating outside of the French-Canadian population.
Subject(s)
Cytochrome-c Oxidase Deficiency/genetics , Mitochondrial Diseases/genetics , Neoplasm Proteins/genetics , Proteins/genetics , Canada , Cells, Cultured , Child, Preschool , Cytochrome-c Oxidase Deficiency/enzymology , Electron Transport Complex IV/metabolism , Female , Fibroblasts/metabolism , Humans , Infant , Infant, Newborn , Leucine-Rich Repeat Proteins , Male , Mitochondrial Diseases/enzymology , Mitochondrial Diseases/metabolism , Mitochondrial Proteins/metabolism , Muscle, Skeletal/metabolism , Mutation , Pedigree , Proteins/metabolism , RNA, Messenger/metabolism , RNA, MitochondrialABSTRACT
Cytochrome c oxidase (CIV) deficiency is one of the most common respiratory chain defects in patients presenting with mitochondrial encephalocardiomyopathies. CIV biogenesis is complicated by the dual genetic origin of its structural subunits, and assembly of a functional holoenzyme complex requires a large number of nucleus-encoded assembly factors. In general, the functions of these assembly factors remain poorly understood, and mechanistic investigations of human CIV biogenesis have been limited by the availability of model cell lines. Here, we have used small interference RNA and transcription activator-like effector nucleases (TALENs) technology to create knockdown and knockout human cell lines, respectively, to study the function of the CIV assembly factor COX20 (FAM36A). These cell lines exhibit a severe, isolated CIV deficiency due to instability of COX2, a mitochondrion-encoded CIV subunit. Mitochondria lacking COX20 accumulate CIV subassemblies containing COX1 and COX4, similar to those detected in fibroblasts from patients carrying mutations in the COX2 copper chaperones SCO1 and SCO2. These results imply that in the absence of COX20, COX2 is inefficiently incorporated into early CIV subassemblies. Immunoprecipitation assays using a stable COX20 knockout cell line expressing functional COX20-FLAG allowed us to identify an interaction between COX20 and newly synthesized COX2. Additionally, we show that SCO1 and SCO2 act on COX20-bound COX2. We propose that COX20 acts as a chaperone in the early steps of COX2 maturation, stabilizing the newly synthesized protein and presenting COX2 to its metallochaperone module, which in turn facilitates the incorporation of mature COX2 into the CIV assembly line.
Subject(s)
Carrier Proteins/metabolism , Cyclooxygenase 2/metabolism , Cytochrome-c Oxidase Deficiency/enzymology , Electron Transport Complex IV/metabolism , Membrane Proteins/metabolism , Mitochondrial Proteins/metabolism , Carrier Proteins/genetics , Cell Line , Cyclooxygenase 2/genetics , Cytochrome-c Oxidase Deficiency/genetics , Cytochrome-c Oxidase Deficiency/metabolism , Electron Transport Complex IV/chemistry , Electron Transport Complex IV/genetics , Humans , Membrane Proteins/genetics , Mitochondria/enzymology , Mitochondria/genetics , Mitochondria/metabolism , Mitochondrial Proteins/genetics , Molecular Chaperones , Protein StabilityABSTRACT
Few therapeutic options are available to patients with oxidative phosphorylation disorders. Administering pharmacological agents that are able to stimulate mitochondrial biogenesis have been put forward as a possible treatment, yet the approach remains in need of thorough testing. We investigated the effect of resveratrol in an in vitro setting. Mitochondrial enzymatic activities were tested in cultured skin fibroblasts from patients harboring a nuclear defect in either complex II or complex IV (n = 11), and in fibroblasts from healthy controls (n = 11). In the latter, preincubation with resveratrol resulted in a significant increase of citrate synthase, complex II and complex IV enzyme activity. In patients with complex II or complex IV deficiency, however, activity of the deficient complex could not be substantially augmented, and response was dependent upon the residual activity. We conclude that resveratrol is not capable of normalizing oxidative phosphorylation activities in deficient cell lines.
Subject(s)
Cytochrome-c Oxidase Deficiency/enzymology , Electron Transport Complex II/deficiency , Fibroblasts/drug effects , Oxidative Phosphorylation/drug effects , Stilbenes/pharmacology , Cells, Cultured , Citrate (si)-Synthase/metabolism , Cytochrome-c Oxidase Deficiency/physiopathology , Electron Transport Complex II/metabolism , Electron Transport Complex IV/genetics , Electron Transport Complex IV/metabolism , Fibroblasts/enzymology , Humans , Mitochondria/drug effects , Mitochondria/enzymology , ResveratrolABSTRACT
Mitochondrial aminoacyl-tRNA synthetases (aaRSs) are essential enzymes in protein synthesis since they charge tRNAs with their cognate amino acids. Mutations in the genes encoding mitochondrial aaRSs have been associated with a wide spectrum of human mitochondrial diseases. Here we report the identification of pathogenic mutations (a partial genomic deletion and a highly conserved p. Asp325Tyr missense variant) in FARS2, the gene encoding mitochondrial phenylalanyl-tRNA synthetase, in a patient with early-onset epilepsy and isolated complex IV deficiency in muscle. The biochemical defect was expressed in myoblasts but not in fibroblasts and associated with decreased steady state levels of COXI and COXII protein and reduced steady state levels of the mt-tRNA(Phe) transcript. Functional analysis of the recombinant mutant p. Asp325Tyr FARS2 protein showed an inability to bind ATP and consequently undetectable aminoacylation activity using either bacterial tRNA or human mt-tRNA(Phe) as substrates. Lentiviral transduction of cells with wildtype FARS2 restored complex IV protein levels, confirming that the p.Asp325Tyr mutation is pathogenic, causing respiratory chain deficiency and neurological deficits on account of defective aminoacylation of mt-tRNA(Phe).
Subject(s)
Amino Acyl-tRNA Synthetases/genetics , Cytochrome-c Oxidase Deficiency/genetics , Epilepsy/genetics , Mitochondria/genetics , Mutation , Amino Acid Sequence , Amino Acyl-tRNA Synthetases/metabolism , Aminoacylation , Child, Preschool , Cyclooxygenase 1/genetics , Cyclooxygenase 1/metabolism , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Cytochrome-c Oxidase Deficiency/complications , Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/pathology , Electron Transport Complex IV/genetics , Electron Transport Complex IV/metabolism , Epilepsy/complications , Epilepsy/enzymology , Epilepsy/pathology , Fibroblasts/cytology , Fibroblasts/metabolism , Gene Expression , Humans , Male , Mitochondria/enzymology , Mitochondria/pathology , Molecular Sequence Data , Muscle, Skeletal/enzymology , Muscle, Skeletal/pathology , Myoblasts/metabolism , Myoblasts/pathology , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Transfer/genetics , RNA, Transfer/metabolismABSTRACT
Cytochrome c oxidase (CIV) deficiency is among the most common childhood mitochondrial disorders. The diagnosis of this deficiency is complex, and muscle biopsy is used as the gold standard of diagnosis. Our aim was to minimize the patient burden and to test the use of a dipstick immunocapture assay (DIA) to determine the amount of CIV in non-invasively obtained buccal epithelial cells. Buccal smears were obtained from five children with Leigh syndrome including three children exhibiting a previously confirmed CIV deficiency in muscle and fibroblasts and two children who were clinical suspects for CIV deficiency; the smear samples were analysed using CI and CIV human protein quantity dipstick assay kits. Samples from five children of similar age and five adults were used as controls. Analysis of the controls demonstrated that only samples of buccal cells that were frozen for a maximum of 4 h after collection provide accurate results. All three patients with confirmed CIV deficiency due to mutations in the SURF1 gene exhibited significantly lower amounts of CIV than the similarly aged controls; significantly lower amounts were also observed in two new patients, for whom later molecular analysis also confirmed pathologic mutations in the SURF1 gene. We conclude that DIA is a simple, fast and sensitive method for the determination of CIV in buccal cells and is suitable for the screening of CIV deficiency in non-invasively obtained material from children who are suspected of having mitochondrial disease.
Subject(s)
Cytochrome-c Oxidase Deficiency/diagnosis , Electron Transport Complex IV/analysis , Epithelial Cells/enzymology , Immunosorbent Techniques , Leigh Disease/diagnosis , Membrane Proteins/genetics , Mitochondrial Proteins/genetics , Mouth Mucosa/pathology , Reagent Strips , Adult , Age of Onset , Case-Control Studies , Cells, Cultured , Child, Preschool , Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/genetics , DNA Mutational Analysis , Electromyography , Electron Transport Complex I/analysis , Failure to Thrive/etiology , Fibroblasts/enzymology , Humans , Infant , Leigh Disease/enzymology , Leigh Disease/genetics , Membrane Proteins/deficiency , Mitochondria, Muscle/enzymology , Mitochondrial Proteins/deficiency , Muscle Hypotonia/etiology , Sequence Deletion , Tremor/etiologySubject(s)
Electron Transport Complex IV/genetics , Genetic Diseases, X-Linked/genetics , Microphthalmos/genetics , Skin Abnormalities/genetics , Skin Diseases, Genetic/genetics , Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/genetics , Electron Transport/genetics , Electron Transport/physiology , Electron Transport Complex IV/chemistry , Female , Genetic Diseases, X-Linked/embryology , Genetic Diseases, X-Linked/pathology , Humans , Infant, Newborn , Lyases/genetics , Male , Microphthalmos/embryology , Microphthalmos/pathology , Mutation , Protein Subunits , Skin/embryology , Skin Abnormalities/embryology , Skin Abnormalities/pathology , Skin Diseases, Genetic/embryology , Skin Diseases, Genetic/pathologyABSTRACT
The age-related deterioration in the central auditory system is well known to impair the abilities of sound localization and speech perception. However, the mechanisms involved in the age-related central auditory deficiency remain unclear. Previous studies have demonstrated that mitochondrial DNA (mtDNA) deletions accumulated with age in the auditory system. Also, a cytochrome c oxidase (CcO) deficiency has been proposed to be a causal factor in the age-related decline in mitochondrial respiratory activity. This study was designed to explore the changes of CcO activity and to investigate the possible relationship between the mtDNA common deletion (CD) and CcO activity as well as the mRNA expression of CcO subunits in the auditory cortex of D-galactose (D-gal)-induced mimetic aging rats at different ages. Moreover, we explored whether peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), nuclear respiratory factor 1 (NRF-1) and mitochondrial transcription factor A (TFAM) were involved in the changes of nuclear- and mitochondrial-encoded CcO subunits in the auditory cortex during aging. Our data demonstrated that d-gal-induced mimetic aging rats exhibited an accelerated accumulation of the CD and a gradual decline in the CcO activity in the auditory cortex during the aging process. The reduction in the CcO activity was correlated with the level of CD load in the auditory cortex. The mRNA expression of CcO subunit III was reduced significantly with age in the d-gal-induced mimetic aging rats. In contrast, the decline in the mRNA expression of subunits I and IV was relatively minor. Additionally, significant increases in the mRNA and protein levels of PGC-1α, NRF-1 and TFAM were observed in the auditory cortex of D-gal-induced mimetic aging rats with aging. These findings suggested that the accelerated accumulation of the CD in the auditory cortex may induce a substantial decline in CcO subunit III and lead to a significant decline in the CcO activity progressively with age despite compensatory increases of PGC-1α, NRF-1 and TFAM. Therefore, CcO may be a specific intramitochondrial site of age-related deterioration in the auditory cortex, and CcO subunit III might be a target in the development of presbycusis.
Subject(s)
Aging/genetics , Aging/metabolism , Auditory Cortex/metabolism , DNA, Mitochondrial/genetics , Electron Transport Complex IV/genetics , Electron Transport Complex IV/metabolism , Animals , Auditory Cortex/ultrastructure , Base Sequence , Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/genetics , Electron Transport Complex IV/chemistry , Gene Expression , Male , Microscopy, Electron, Transmission , Nuclear Respiratory Factor 1/genetics , Nuclear Respiratory Factor 1/metabolism , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha , Protein Subunits , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , Rats , Rats, Sprague-Dawley , Sequence Deletion , Transcription Factors/genetics , Transcription Factors/metabolismABSTRACT
Renal manifestations of mitochondrial cytopathies have been described, but nephrotic syndrome with respiratory-chain disorders have been described extremely rarely. We report a 9-month-old boy with a mitochondrial cytopathy preceded by a 2-month history of steroid-resistant nephrotic syndrome. Percutaneous renal biopsy revealed diffuse mesangial sclerosis, and mutational analysis was compatible with PLCE1 mutation. However, electron microscopic findings of renal tissue, sensorineural hearing loss, and other ocular and neurologic findings led us to suspect mitochondrial cytopathy. Muscle tissue analysis showed a deficiency of the respiratory chain complex IV. The clinical presentation of our patient is not typical for primary cytochrome oxidase (COX) deficiency but showed similarities with patients carrying AR mutations in COX10. This was the first case in the literature with both PLCE1 mutation and COX deficiency. We could not identify pathogenic mutations in the COX10 gene, suggesting that PLCE1 deficiency could be the cause of the secondary deficiency of COX. Another, more likely, possibility is that the mitochondriopathy phenotype is caused by another mutation homozygous by descent in a yet unidentified recessive gene.
Subject(s)
Alkyl and Aryl Transferases/genetics , Cytochrome-c Oxidase Deficiency/diagnosis , Membrane Proteins/genetics , Nephrotic Syndrome/diagnosis , Phosphoinositide Phospholipase C/genetics , Sclerosis/diagnosis , Alkyl and Aryl Transferases/deficiency , Biopsy , Cytochrome-c Oxidase Deficiency/complications , Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/genetics , Cytochrome-c Oxidase Deficiency/therapy , DNA Mutational Analysis , Electron Transport Complex IV , Genetic Predisposition to Disease , Humans , Infant , Male , Membrane Proteins/deficiency , Mutation , Nephrotic Syndrome/enzymology , Nephrotic Syndrome/genetics , Nephrotic Syndrome/therapy , Phenotype , Sclerosis/enzymology , Sclerosis/genetics , Sclerosis/therapyABSTRACT
We have recently identified mutations in the translation activator of cytochrome c oxidase 1 (TACO1) gene, leading to cytochrome c oxidase (COX) deficiency. Here, we report the clinical and neuroimaging findings of five members of a big consanguinous family homozygous for c.472insC in TACO1. All 5 patients had an uneventful early childhood and a subtle onset, slowly progressive cognitive dysfunction, dystonia or visual impairment between ages 4 and 16years. Affected girls had a milder phenotype and preserved ambulation into the late twenties. Brain MRI revealed bilateral, symmetric lesions of the basal ganglia in all affected family members, but less prominent in girls. TACO1 analysis showed no mutations in 17 patients with juvenile-onset Leigh syndrome and isolated COX or combined respiratory chain deficiency, indicating that TACO1 mutations are a rare cause of Leigh syndrome.
Subject(s)
Basal Ganglia/pathology , Cognition Disorders/genetics , Cytochrome-c Oxidase Deficiency/genetics , Microfilament Proteins/genetics , Muscle, Skeletal/pathology , Adolescent , Adult , Child , Cognition Disorders/enzymology , Cognition Disorders/pathology , Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/pathology , Electron Transport Complex IV/genetics , Electron Transport Complex IV/metabolism , Female , Humans , Leigh Disease/genetics , Leigh Disease/pathology , Magnetic Resonance Imaging , Male , Microfilament Proteins/metabolism , Muscle, Skeletal/enzymology , Phenotype , Sex FactorsABSTRACT
Mutations in SCO2, a protein required for the proper assembly and functioning of cytochrome c oxidase (COX; complex IV of the mitochondrial respiratory chain), cause a fatal infantile cardioencephalomyopathy with COX deficiency. We have generated mice harboring a Sco2 knock-out (KO) allele and a Sco2 knock-in (KI) allele expressing an E-->K mutation at position 129 (E129K), corresponding to the E140K mutation found in almost all human SCO2-mutated patients. Whereas homozygous KO mice were embryonic lethals, homozygous KI and compound heterozygous KI/KO mice were viable, but had muscle weakness; biochemically, they had respiratory chain deficiencies as well as complex IV assembly defects in multiple tissues. There was a concomitant reduction in mitochondrial copper content, but the total amount of copper in examined tissues was not reduced. These mouse models should be of use in further studies of Sco2 function, as well as in testing therapeutic approaches to treat the human disorder.
Subject(s)
Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/genetics , Electron Transport Complex IV/genetics , Mutation/genetics , Animals , Blotting, Western , Copper/metabolism , Disease Models, Animal , Embryo, Mammalian/enzymology , Embryo, Mammalian/pathology , Enzyme Assays , Immunohistochemistry , Mice , Mice, Knockout , Mitochondria/metabolism , Molecular Chaperones , Muscles/enzymology , Muscles/pathology , Organ SpecificityABSTRACT
Cytochrome c oxidase (COX) deficiency is associated with a wide spectrum of clinical conditions, ranging from early onset devastating encephalomyopathy and cardiomyopathy, to neurological diseases in adulthood and in the elderly. No method of compensating successfully for COX deficiency has been reported so far. In vitro, COX-deficient human cells require additional glucose, pyruvate and uridine for normal growth and are specifically sensitive to oxidative stress. Here, we have tested whether the expression of a mitochondrially targeted, cyanide-resistant, alternative oxidase (AOX) from Ciona intestinalis could alleviate the metabolic abnormalities of COX-deficient human cells either from a patient harbouring a COX15 pathological mutation or rendered deficient by silencing the COX10 gene using shRNA. We demonstrate that the expression of the AOX, well-tolerated by the cells, compensates for both the growth defect and the pronounced oxidant-sensitivity of COX-deficient human cells.
Subject(s)
Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/pathology , Genetic Complementation Test , Oxidoreductases/metabolism , Alkyl and Aryl Transferases/deficiency , Alkyl and Aryl Transferases/metabolism , Animals , Antimycin A/analogs & derivatives , Antimycin A/pharmacology , Cell Line, Transformed , Cell Survival/drug effects , Ciona intestinalis/enzymology , Electron Transport/drug effects , Electron Transport Complex IV , Fibroblasts/drug effects , Fibroblasts/enzymology , Gene Knockdown Techniques , Humans , Hydrogen Peroxide/pharmacology , Membrane Proteins/deficiency , Membrane Proteins/metabolism , Mitochondrial Proteins , Mutation/genetics , Oxidative Stress/drug effects , Plant Proteins , Skin/pathologyABSTRACT
Cytochrome c oxidase (COX) deficiency, one of the most common respiratory-chain defects in humans, has been associated with mutations in either mitochondrial DNA genes or nucleus-encoded proteins that are not part in but promote the biogenesis of COX. Mutations of nucleus-encoded structural subunits were sought for but never found in COX-defective patients, leading to the conjecture that they may be incompatible with extra-uterine survival. We report a disease-associated mutation in one such subunit, COX6B1. Nuclear-encoded COX genes should be reconsidered and included in the diagnostic mutational screening of human disorders related to COX deficiency.
Subject(s)
Brain Diseases, Metabolic, Inborn/enzymology , Brain Diseases, Metabolic, Inborn/genetics , Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/genetics , Electron Transport Complex IV/genetics , Point Mutation , Amino Acid Sequence , Amino Acid Substitution , Base Sequence , Brain/pathology , Brain Diseases, Metabolic, Inborn/pathology , Cell Nucleus/enzymology , Cell Nucleus/genetics , Child , Cytochrome-c Oxidase Deficiency/pathology , Electron Transport Complex IV/chemistry , Female , Genetic Complementation Test , Haplotypes , HeLa Cells , Humans , Infant , Magnetic Resonance Imaging , Male , Models, Molecular , Molecular Sequence Data , Pedigree , Protein Conformation , RNA Interference , Sequence Homology, Amino AcidABSTRACT
G93A SOD1 transgenic mice overexpressing CCS protein develop an accelerated disease course that is associated with enhanced mitochondrial pathology and increased mitochondrial localization of mutant SOD1. Because these results suggest an effect of mutant SOD1 on mitochondrial function, we assessed the enzymatic activities of mitochondrial respiratory chain complexes in the spinal cords of CCS/G93A SOD1 and control mice. CCS/G93A SOD1 mouse spinal cord demonstrates a 55% loss of complex IV (cytochrome c oxidase) activity compared with spinal cord from age-matched non-transgenic or G93A SOD1 mice. In contrast, CCS/G93A SOD1 spinal cord shows no reduction in the activities of complex I, II, or III. Blue native gel analysis further demonstrates a marked reduction in the levels of complex IV but not of complex I, II, III, or V in spinal cords of CCS/G93A SOD1 mice compared with non-transgenic, G93A SOD1, or CCS/WT SOD1 controls. With SDS-PAGE analysis, spinal cords from CCS/G93A SOD1 mice showed significant decreases in the levels of two structural subunits of cytochrome c oxidase, COX1 and COX5b, relative to controls. In contrast, CCS/G93A SOD1 mouse spinal cord showed no reduction in levels of selected subunits from complexes I, II, III, or V. Heme A analyses of spinal cord further support the existence of cytochrome c oxidase deficiency in CCS/G93A SOD1 mice. Collectively, these results establish that CCS/G93A SOD1 mice manifest an isolated complex IV deficiency which may underlie a substantial part of mutant SOD1-induced mitochondrial cytopathy.
Subject(s)
Alanine/genetics , Amino Acid Substitution , Cytochrome-c Oxidase Deficiency/enzymology , Glycine/genetics , Molecular Chaperones/metabolism , Superoxide Dismutase/metabolism , Animals , Electrophoresis, Polyacrylamide Gel , Heme/metabolism , Humans , Kidney/enzymology , Mice , Mice, Transgenic , Organ Specificity , Oxidative Phosphorylation , Protein Subunits/metabolism , Spinal Cord/enzymologyABSTRACT
BACKGROUND: MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) is one of the more common mitochondrial encephalomyopathies. About 80% of MELAS cases are caused by transition 3243A-->G in the mitochondrial tRNA(Leu(UUR)) gene (MT-TL1). Other mutations in MT-TL1, other mitochondrial tRNA genes and mitochondrial-encoded subunits of respiratory complex I account for the remainder of cases. OBJECTIVE: To characterise the molecular basis of a MELAS case without a mutation in any recognised MELAS target gene. RESULTS AND METHODS: Deletion of a single nucleotide (7630delT) within MT-CO2, the gene of subunit II of cytochrome c oxidase (COX), was identified by mitochondrial DNA (mtDNA) sequencing. The deletion-induced frameshift results in a stop codon close to the 5' end of the reading frame. The lack of subunit II (COII) precludes the assembly of COX and leads to the degradation of unassembled subunits, even those not directly affected by the mutation. Despite mitochondrial proliferation and transcriptional upregulation of nuclear and mtDNA-encoded COX genes (including MT-CO2), a severe COX deficiency was found with all investigations of the muscle biopsy (histochemistry, biochemistry, immunoblotting). CONCLUSIONS: The 7630delT mutation in MT-CO2 leads to a lack of COII with subsequent misassembly and degradation of respiratory complex IV despite transcriptional upregulation of its subunits. The causal association of the resulting isolated COX deficiency with MELAS is at odds with current concepts of the biochemical deficits underlying this common mitochondrial disease, and indicates that the genetic and pathobiochemical heterogeneity of MELAS is greater than previously appreciated.
Subject(s)
Cytochrome-c Oxidase Deficiency/enzymology , Cytochrome-c Oxidase Deficiency/genetics , Electron Transport Complex IV/genetics , MELAS Syndrome/enzymology , MELAS Syndrome/genetics , Adult , Amino Acid Sequence , Base Sequence , Cytochrome-c Oxidase Deficiency/complications , DNA, Mitochondrial/genetics , Humans , MELAS Syndrome/etiology , MELAS Syndrome/pathology , Male , Molecular Sequence Data , Muscles/enzymology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Sequence DeletionABSTRACT
BACKGROUND: Cytochrome-c oxidase (COX) is the terminal enzyme of the mitochondrial electron transport chain, and COX deficiency is a common cause of mitochondrial diseases. Cytochrome-c oxidase is composed of 13 subunits, of which 3 are encoded by mitochondrial DNA and 10 by nuclear DNA. Mutations have been identified in each of the 3 mitochondrial DNA genes but in none of the nuclear DNA genes. However, COX deficiency has been attributed to mutations in several nuclear DNA-encoded ancillary proteins needed for COX assembly and function. Despite this progress, the molecular basis of COX deficiency remains elusive in many patients, justifying the identification and screening of additional COX assembly genes, such as COX16, COX19, and PET191. OBJECTIVE: To determine if COX16, COX19, and PET191 are implicated in human COX deficiency. METHODS: Mutation screening was performed on 53 patients with isolated COX deficiency by direct sequencing of COX19 and by single-strand conformational polymorphism analysis for COX16 and PET191. RESULTS: No mutations were found in COX16, COX19, or PET191 in these patients. CONCLUSIONS: The COX16, COX19, and PET191 genes are either not involved or very rarely involved in human COX deficiency. Mutations in additional COX assembly genes remain to be identified.